Abstract | BACKGROUND: PATIENTS AND METHODS: The presence or absence of erbB4 kinase domain mutations was analyzed by reverse-transcription polymerase chain reaction amplification and direct sequencing in 105 surgically treated non-small-cell lung cancer cases from Nagoya City University Hospital. Sixty-three adenocarcinoma cases were included. The EGFR mutation status for these 105 samples were already reported. We have investigated erbB4 expression status by immunohistochemistry in 40 non-small cell lung cancer cases. RESULTS: ErbB4 mutation was not found in 105 patients with lung cancer. The EGFR mutation status was significantly correlated with sex (women, 74.2% vs. men, 9.5%; P < 0.0001), smoking status (never-smokers, 68.8% vs. smokers, 11%; P < 0.0001), pathologic subtype ( adenocarcinoma, 44.4% vs. non- adenocarcinoma, 4.8%; P < 0.0001), and differentiation status of the lung cancer (well-differentiated, 47.4% vs. others, 14.8%; P = 0.0004). We detected ErbB4 protein positivity in 20 samples. The ErbB4 protein status was not significantly correlated with sex (women, 28.6% vs. men, 54.5%; P = 0.4075), smoking status (never-smokers, 69.4% vs. smokers, 16.9%; P < 0.0001), pathologic subtype ( adenocarcinoma, 46.2% vs. nonadenocarcinoma, 51.9%; P > 0.9999), or differentiation status of the lung cancer (well-differentiated, 54.5% vs. others, 48.3%; P > 0.9999). CONCLUSION:
|
Authors | Hidefumi Sasaki, Katsuhiro Okuda, Osamu Kawano, Katsuhiko Endo, Haruhiro Yukiue, Tomoki Yokoyama, Motoki Yano, Yoshitaka Fujii |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 8
Issue 7
Pg. 429-33
(Jul 2007)
ISSN: 1525-7304 [Print] United States |
PMID | 17681096
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- ERBB4 protein, human
- ErbB Receptors
- Receptor, ErbB-4
|
Topics |
- Adenocarcinoma
(genetics)
- Aged
- Antineoplastic Agents
(therapeutic use)
- Disease Progression
- ErbB Receptors
(antagonists & inhibitors, biosynthesis, genetics, physiology)
- Female
- Humans
- Immunohistochemistry
- Japan
- Lung Neoplasms
(drug therapy, genetics)
- Male
- Middle Aged
- Mutation
(genetics)
- Neoplasm Staging
- Polymorphism, Genetic
- Prognosis
- Receptor, ErbB-4
|